Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations

3 Views
Published
A roundtable discussion, moderated by Jigarkumar Parikh, MD, MBBS, highlighted the evolving landscape of prostate cancer treatment through the integration of multi-specialty collaboration, the introduction of new therapies and their challenges, and the crucial role of molecular and genetic testing in personalizing patient care and improving long-term outcomes. Dr. Parikh was joined by Joshua Perkel, MD; Rajesh Laungani, MD; Joseph Bear, MD; and Marc Greenstein, DO.

In the third segment of the roundtable series, the panel delves into the implementation of triplet therapy for mHSPC, highlighting the significance of effective communication with patients about the benefits and logistics of the ARASENS regimen, the collaborative efforts between urologists and medical oncologists, and the need for ongoing attention to patient quality of life throughout long-term treatment.
Category
Urology
Be the first to comment